Navigation Links
DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Date:8/19/2007

SOMERSET, N.J., Aug. 9 /PRNewswire-FirstCall/ -- DOV Pharmaceutical, Inc. ("DOV" or the "Company") (Pink Sheets: DOVP.PK) today announced Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor ("TRIP") for the treatment of depression and obesity. Preliminary analysis of the study results indicates DOV 21,947 was safe and well-tolerated at the doses examined and produced a significant decline in plasma triglyceride levels. The Company intends to initiate a Phase II study of DOV 21,947 for the treatment of depression in the fourth quarter of this year.

"Prior studies with DOV 21,947 at up to 100 mg per day demonstrated the safety and tolerability of this compound over dosing periods of up to ten days. The goal of this Phase Ib study was to confirm DOV 21,947's safety and tolerability over an eight-week period at escalating doses of up to 150 mg per day. These data give us added confidence in the drug's safety and tolerability in preparation for our upcoming Phase II trial in patients with major depressive disorder. The significant reductions in plasma triglyceride levels observed during the conduct of this study are consistent with preclinical evidence that DOV 21,947 is able to produce a significant and sustained reduction in both triglyceride levels and body weight in animal models of obesity. These findings underscore the therapeutic versatility of triple reuptake inhibitors such as DOV 21,947," said Dr. Phil Skolnick, President and Chief Scientific Officer of DOV.

This double-blind, placebo-controlled Phase Ib study enrolled 46 male and female subjects. Following a one-week placebo run-in, subjects received either escalating daily doses of 50 mg, 100 mg and 150 mg of DOV 21,947 (31 subjects) or placebo (15 subjects), for a total of eight weeks. The study demonstrated that DOV 21,947 was safe and well-tolerated in this dose range with no reported serious adverse events. The proportion of patients with treatment emergent adverse event
'/>"/>

SOURCE DOV Pharmaceutical, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...LYMOUTH MEETING, Pa., Nov. 20 /PRNewswire-USNewswi...ticle that questions why currently available medic...are being ignored, ECRI Institute, an independent ...he evidence on Finasteride for Prevention of Pros...er 13, 2009, New York Times article, " Drugs to ...
(Date:11/20/2009)...IS, Tenn., Nov. 20 Smi...ion is pleased to announce the signing of a techno...epartment of Defense that may lead to the creation...ionize the treatment of the limbs of soldiers who ... Defense Advanced Research Projects Agency (DARPA)...
(Date:11/19/2009)...EE, Ireland, Nov. 19 Warner Chilco...g of its previously announced secondary offering o...the public of $22.25 per share. The selling share... Partners, DLJ Merchant Banking, J.P. Morgan Partn...rtners, L.P., certain other institutional investor...
Breaking Medicine Technology:ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4Connectyx Partners with I DENTI FIED Inc to Add RFID Transponder Technology as Part of its MedFlash Personal Health Record 48157 1Connectyx Partners with I DENTI FIED Inc to Add RFID Transponder Technology as Part of its MedFlash Personal Health Record 48157 2Connectyx Partners with I DENTI FIED Inc to Add RFID Transponder Technology as Part of its MedFlash Personal Health Record 48157 3Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 1Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 2Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 3Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 4Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Associat 12518 5Pasteuria Bioscience Receives EPA Registration for Nematode Control 12514 1Pasteuria Bioscience Receives EPA Registration for Nematode Control 12514 2
...mpound, AHLi-11, Slated for IND Filing By ...f., Aug. 20 Quark Pharmaceuticals, Inc., a,clinic...overing and,developing novel RNA interference-base...ed its relationship with the State University of N... which is the Company,s primary site,for the pre-c...
...baxy Pharmaceuticals Inc.,(RPI), a wholly owned su...ounced today that RLL has received approval from t...e and market Hydrocodone Bitartrate and,Acetaminop.../500 mg, and 10,mg/325 mg strengths. The Office of... has determined the Ranbaxy formulations to be bio...
Other Medicine Technology:Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 2Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 3Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss 4Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP 2
(Date:11/20/2009)... thinks it,s as short as 34 weeks, potentially add... , FRIDAY, Nov. 20 (HealthDay News) -- Recent r...ntinues to climb in the United States. Now, a new...fused about what constitutes a full-term birth in ...hers surveyed in the study considered a baby born ...
(Date:11/20/2009)...lu activity remains high and is expected to contin...thDay News) -- Some areas of the United States are...eral health official said Friday, and while the di... from the 46 states reported last week. , "We a...ivity around the country, but there is still a lot...
(Date:11/20/2009)..., SPRINGFIELD, Mo., Nov. 20 Mis...entral Missouri regions will now have the option t... reached Tuesday between Missouri Consolidated Hea..., The Southwest and South Central Missouri regions...dar, Christian, Dade, Dallas, Douglas, Greene, Hic...
(Date:11/20/2009)..., BATON ROUGE, La., Nov. 20 /PRNewswire-USNew...ans (LAHP) today warned that Louisianians could ex...enefits if proposals being considered by Congress ...hief executive officer for LAHP, "Louisiana health...form since the beginning of the national debate. ...
(Date:11/20/2009)..., LANSING, Mich., Nov. 20 /PRNewswire-USNewswir...n seven Americans struggled to get enough food to ...iculties of older adults who are rapidly aging int...death of a spouse or divorce mean many have income... housing and medicine. Older women are particular...
Breaking Medicine News(10 mins):Health News:Many Women Miscalculate Time to Full-Term Birth 2Health News:Many Women Miscalculate Time to Full-Term Birth 3Health News:Many Women Miscalculate Time to Full-Term Birth 4Health News:Swine Flu Declining in Some Parts of U.S. 2Health News:Swine Flu Declining in Some Parts of U.S. 3Health News:Missouri Consolidated Health Care Plan Provides Mercy Health Plans Option 2Health News:Congressional Health Care Reform Proposals Would Make Health Care More Expensive, Reduce Benefits for Louisianians 2
... solution allows visionary healthcare organization... Information stored in email , , NEWTON, Mass., A...ing, continuity and security, today announced Uni...00 email users. As email has become the de facto ...
...ril 6 The National Sexual Violence Resource Cente...ts of the Visionary Voice Award . This award re... of individuals around the country working to addr...wide range of individuals doing this critical work...
...Provides Glimpse into the Future of Improved Patie...formation , , CHICAGO, April 6 (HIMSS,09, Booth ...emonstrating its advanced solution for global medi...mpany is leveraging technology originally develope...
...al Device Company invites customers to just ,have ...re experiences. , , ENGLEWOOD, Colo., April 6 Ba...for the safe handling, packaging and administratio...thcare facilities, medical device companies and ho...
... Mich., April 6 , , "The first rule of any tec...ied to an efficient operation will magnify the eff...an inefficient operation will magnify the ineffici...al-time asset tracking and automated charge captur...
...an suggests what,s worth trying, what to avoid , ...than ever are being treated with complementary and...hat about 30 percent of healthy children and up to...ve medicine in pediatrics," says Dolores Mendelow,...
Other Medicine News:Health News:University of Tennessee Medical Center Saves 60 Percent on IT Costs With Unified Email Management by Mimecast 2Health News:University of Tennessee Medical Center Saves 60 Percent on IT Costs With Unified Email Management by Mimecast 3Health News:Harris Corporation Demonstrates Global Medical Imagery Access, Sharing and Collaboration Capabilities 2Health News:Harris Corporation Demonstrates Global Medical Imagery Access, Sharing and Collaboration Capabilities 3Health News:Baxa Corporation Gets Social With Facebook and LinkedIn 2Health News:Baxa Corporation Gets Social With Facebook and LinkedIn 3Health News:Children's Hospital of Wisconsin Extends Real-Time Asset Tracking and Automated Charge Capture to their New Patient Pavilion 2Health News:Children's Hospital of Wisconsin Extends Real-Time Asset Tracking and Automated Charge Capture to their New Patient Pavilion 3Health News:Children's Hospital of Wisconsin Extends Real-Time Asset Tracking and Automated Charge Capture to their New Patient Pavilion 4Health News:Alternative Therapies Can Be Safe, Effective For Children 2Health News:Alternative Therapies Can Be Safe, Effective For Children 3
Full Handle Laseredge Implant Blade Knife, 3.5 mm round tip
Full Handle Laseredge Crescent Blade Knife, angled bevel down
Full Handle Laseredge Stab Blade Knife, 45 blade
Disposable Bipolar Pencil - 23 Gauge Tapered Tip
Medicine Products: